Inhibikase Therapeutics (IKT)
What the price implies
A reverse DCF: instead of guessing a fair value, it asks what growth today's price already assumes. How it works.
Fundamental grade
Five factors scored 1 to 9 from IKT's latest numbers, weighted into one grade. It describes the business, not whether the stock is a buy.
Results from SEC filings
Fiscal years, from Inhibikase Therapeutics's 10-K filings. Ten years of the full income statement, balance sheet and cash flow.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $3M | $123,440 | $260,501 | $0 | — |
| Net income | -$15M | -$18M | -$19M | -$28M | -$48M |
| Free cash flow | -$14M | -$18M | -$18M | -$19M | -$28M |
| EPS (diluted) | -$4.86 | -$4.28 | -$3.16 | -$1.16 | -$0.49 |
| Operating margin | -476.2% | -14686.2% | -7712.0% | — | — |
Superinvestors who own IKT
From each investor's latest 13F filing (what a 13F shows). 1 of the investors we track hold it.
| Investor | Last quarter | Value | % of portfolio | Quarter |
|---|---|---|---|---|
| Cliff Asness AQR Capital Management |
Added | $950,440 | 0.0% | Q2 2026 |
Insider buying
Open-market purchases by Inhibikase Therapeutics's executives and directors in the last 12 months, from SEC Form 4 filings. What insider buying tells you.
Get an alert at your buy price
Pick the price you'd be interested at. We'll email you when IKT trades at or below it.
New accounts get 7 days of Pro, price alerts included. No card needed.
In the full deep dive
Questions
Are Inhibikase Therapeutics insiders buying the stock?
No open-market insider purchases of IKT in the last 12 months, according to SEC Form 4 filings.
Which superinvestors own Inhibikase Therapeutics?
1 of the superinvestors Investingly tracks hold IKT in their latest 13F, including Cliff Asness.
Prices and ratios as of Oct 11, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.